Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.39 USD | -3.80% | +2.17% | +41.83% |
Mar. 19 | Morphic Holding Names Simon Cooper as Chief Medical Officer | MT |
Mar. 15 | Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug | MT |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+41.83% | 2.03B | C- | ||
-3.46% | 102B | B+ | ||
+1.41% | 96.09B | B+ | ||
+2.13% | 22.28B | B | ||
-15.84% | 21.4B | B+ | ||
-9.21% | 18.14B | A- | ||
-39.98% | 17.02B | A- | ||
-14.65% | 16.09B | B | ||
+4.39% | 13.83B | C+ | ||
+31.35% | 11.97B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KROS Stock
- Ratings Keros Therapeutics, Inc.